What are the key
ingredients for
success of the vaccine
industry in India?
Please list out the
top five milestones
of the Indian vaccine
industry so far?
The vaccine industry is
driven by its capability to
supply high volume yet
high quality vaccines for
addressing global public
health needs. The industry
has established a high
reputation for doing so by
repeatedly accomplishing
this for several
established and emerging
vaccines. Indian
vaccine companies have
excelled at successfully
collaborating with global
academic and corporate
partners for technology
access and product
development, been
adept at adopting new
technologies and working
with global public health
authorities to proactively
address immunization
priorities. Lastly, an
active and critical role
has been played by the
Indian Government
and regulator. Having
a National Regulatory
Authority recognized
by WHO has enabled
several Indian companies
to wade through WHO
prequalification process
efficiently and participate
in global procurement
processes.
The Indian vaccine
industry has time and
again, broken affordability
barriers, addressed
technology challenges and
has earned India a special
place in the global arena.
Noteworthy achievements
of the industry include:
● Addressing close to
100 percent of Indian
immunization needs with
affordable yet technically
advanced vaccines
produced domestically.
There is minimal import
dependency and India is
largely self-sufficient for
vaccines for the national
immunization program,
a stellar Make-in-India
success story chartered
over the last two decades.
● Proactive technology
adoption and ensuring
Indians have access to
vaccines that are not
affordable but are also
contemporary - Shantha
Biotech and Bharat
Biotech’s indigenous
Hepatitis B vaccine
Our analysis
indicates that
the industry grew
to approximately
$1 billion in 2015
with a robust CAGR
of 25 percent
between 2011
and 2015. Exports
are the dominant
revenue source
for Indian vaccine
industry today,
accounting for
a dominant 69
percent share in
value
(the first recombinant
vaccines to be produced
in India) which brought
down the vaccine cost
from $ 23 a dose to $1
a dose. Similarly, the
industry has repeated this
success for pentavalent
vaccines, more recently
the rotavirus vaccine and
is currently in the process
of doing so for the PCV
vaccine.
● Extending the
breakthrough cost and
affordability advantage
BIOVOICENEWS.COM
31